Intuitive Surgical (NASDAQ:ISRG) Upgraded to “Buy” at Erste Group Bank

Intuitive Surgical (NASDAQ:ISRG) was upgraded by equities researchers at Erste Group Bank from a “hold” rating to a “buy” rating in a research note issued on Wednesday, Briefing.com reports.

A number of other research firms have also recently issued reports on ISRG. Royal Bank Of Canada cut their price objective on Intuitive Surgical from $650.00 to $600.00 and set an “outperform” rating for the company in a report on Monday, July 13th. BNP Paribas Exane upgraded Intuitive Surgical to an “outperform” rating in a research report on Tuesday, July 28th. BTIG Research reduced their price target on shares of Intuitive Surgical from $469.00 to $454.00 and set a “buy” rating on the stock in a research report on Monday, October 12th. Oppenheimer raised shares of Intuitive Surgical from a “market perform” rating to an “outperform” rating and set a $500.00 price objective for the company in a research note on Wednesday, August 12th. Finally, Barclays raised shares of Intuitive Surgical to a “strong-buy” rating in a report on Wednesday, October 7th. Twenty-five analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $498.72.

Intuitive Surgical Stock Up 1.1%

NASDAQ ISRG opened at $438.00 on Wednesday. The company has a market cap of $154.74 billion, a PE ratio of 50.17, a price-to-earnings-growth ratio of 3.27 and a beta of 1.46. Intuitive Surgical has a 52 week low of $328.57 and a 52 week high of $603.88. The firm’s 50-day simple moving average is $392.96 and its two-hundred day simple moving average is $409.06.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.35. The business had revenue of $3.05 billion for the quarter, compared to analysts’ expectations of $2.91 billion. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%. The firm’s quarterly revenue was up 21.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.40 EPS. As a group, equities research analysts anticipate that Intuitive Surgical will post 8.87 EPS for the current year.

Insider Buying and Selling

In related news, VP Fredrik Widman sold 1,089 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $374.44, for a total value of $407,765.16. Following the transaction, the vice president owned 1,026 shares of the company’s stock, valued at approximately $384,175.44. This trade represents a 51.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy Ladd sold 400 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $379.00, for a total transaction of $151,600.00. Following the sale, the director owned 251 shares of the company’s stock, valued at $95,129. This trade represents a 61.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 12,370 shares of company stock valued at $4,891,989 in the last 90 days. 0.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Intuitive Surgical

Institutional investors have recently bought and sold shares of the business. Bank of America Corp DE raised its position in Intuitive Surgical by 3.3% during the 1st quarter. Bank of America Corp DE now owns 3,616,973 shares of the medical equipment provider’s stock valued at $1,667,388,000 after purchasing an additional 116,292 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Intuitive Surgical during the second quarter valued at about $1,335,753,000. Amundi increased its holdings in shares of Intuitive Surgical by 8.6% during the first quarter. Amundi now owns 2,428,356 shares of the medical equipment provider’s stock valued at $1,119,448,000 after acquiring an additional 193,096 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Intuitive Surgical by 95.3% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider’s stock valued at $970,635,000 after purchasing an additional 1,027,475 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Intuitive Surgical by 13.8% in the first quarter. Assenagon Asset Management S.A. now owns 1,745,008 shares of the medical equipment provider’s stock worth $804,431,000 after buying an additional 211,237 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Key Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Q3 results exceeded expectations: Revenue rose 21.7% year over year to $3.05 billion, above the approximately $2.91 billion consensus, while adjusted earnings reached $3.00 per share versus estimates of roughly $2.61–$2.65. Intuitive Surgical Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: Underlying demand remained healthy: Worldwide procedures increased approximately 15%, including 14% growth for da Vinci procedures and 31% for Ion procedures. Intuitive placed 546 robotic systems, up from 427 a year earlier. Intuitive Announces Third Quarter Earnings
• Positive Sentiment: Potentially broader adoption: Intuitive plans to extend instrument life and reduce per-procedure costs in 2027. Although this could pressure near-term revenue per procedure, management views it as a way to make robotic surgery more affordable and expand the installed base. Why ISRG Is Lowering Instrument Costs Despite Strong Profitability
• Neutral Sentiment: Leasing is supporting placements: Operating leases represented 54% of second-quarter da Vinci placements, up from 49% a year earlier. Leasing may accelerate hospital adoption, but it can also make Intuitive’s returns more dependent on future procedure volume. Does Leasing Make Growth More Durable or More Capital Intensive?
• Negative Sentiment: Large antitrust settlement charge hurt GAAP earnings: Intuitive recorded a $450 million pre-tax charge, or $347 million after tax, related to a proposed settlement. GAAP net income fell to $523 million, or $1.49 per share, from $704 million, or $1.95 per share, a year earlier; court approval is still required. Antitrust Settlement Charge Overshadows Strong Q3 Growth
• Negative Sentiment: 2026 procedure-growth guidance was narrowed to 14%–15%: The tighter outlook, along with planned pricing actions targeting a 3%–5% reduction in instrument and accessory costs per procedure, raised concerns that growth and margins may moderate. Intuitive Narrows 2026 Procedure Growth Outlook

About Intuitive Surgical

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.